ZA200507235B - Treating immunological disorders using agonists of interleukin-21/interleukin-21 receptor - Google Patents

Info

Publication number

ZA200507235B

ZA200507235B ZA200507235A ZA200507235A ZA200507235B ZA 200507235 B ZA200507235 B ZA 200507235B ZA 200507235 A ZA200507235 A ZA 200507235A ZA 200507235 A ZA200507235 A ZA 200507235A ZA 200507235 B ZA200507235 B ZA 200507235B

Authority

ZA

South Africa

Prior art keywords

agonist

polypeptide

subject

human

parameter

Prior art date

2003-03-21

Links

• Espacenet
• Global Dossier
• Discuss

• 108010074108 interleukin-21 Proteins 0.000 title claims description 306
• 102100030704 Interleukin-21 Human genes 0.000 title claims description 234
• 239000000556 agonist Substances 0.000 title claims description 218
• 108010017411 Interleukin-21 Receptors Proteins 0.000 title claims description 183
• 102000004527 Interleukin-21 Receptors Human genes 0.000 title claims description 183
• 208000026278 immune system disease Diseases 0.000 title claims description 30
• 238000000034 method Methods 0.000 claims description 107
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 100
• 108090000623 proteins and genes Proteins 0.000 claims description 96
• 241000282414 Homo sapiens Species 0.000 claims description 90
• 210000004027 cell Anatomy 0.000 claims description 85
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 79
• 239000012634 fragment Substances 0.000 claims description 77
• 229920001184 polypeptide Polymers 0.000 claims description 77
• 102000004169 proteins and genes Human genes 0.000 claims description 76
• 108090000174 Interleukin-10 Proteins 0.000 claims description 75
• 102000003814 Interleukin-10 Human genes 0.000 claims description 75
• 201000006417 multiple sclerosis Diseases 0.000 claims description 65
• 239000003814 drug Substances 0.000 claims description 44
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 41
• 239000005557 antagonist Substances 0.000 claims description 38
• 230000000694 effects Effects 0.000 claims description 38
• 239000008194 pharmaceutical composition Substances 0.000 claims description 35
• 239000000427 antigen Substances 0.000 claims description 32
• 108091007433 antigens Proteins 0.000 claims description 32
• 102000036639 antigens Human genes 0.000 claims description 32
• 208000024891 symptom Diseases 0.000 claims description 27
• 230000014509 gene expression Effects 0.000 claims description 26
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
• 238000011282 treatment Methods 0.000 claims description 24
• 230000001270 agonistic effect Effects 0.000 claims description 21
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 21
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 17
• 229960002930 sirolimus Drugs 0.000 claims description 17
• 238000004519 manufacturing process Methods 0.000 claims description 16
• 239000002260 anti-inflammatory agent Substances 0.000 claims description 14
• 208000035475 disorder Diseases 0.000 claims description 14
• 101001010621 Homo sapiens Interleukin-21 Proteins 0.000 claims description 13
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 13
• 229940121363 anti-inflammatory agent Drugs 0.000 claims description 13
• 108010065805 Interleukin-12 Proteins 0.000 claims description 12
• 229960000485 methotrexate Drugs 0.000 claims description 12
• 230000001580 bacterial effect Effects 0.000 claims description 11
• 230000007812 deficiency Effects 0.000 claims description 11
• 108010072051 Glatiramer Acetate Proteins 0.000 claims description 10
• VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims description 9
• 229960000681 leflunomide Drugs 0.000 claims description 9
• 230000001225 therapeutic effect Effects 0.000 claims description 9
• CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims description 8
• 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 8
• 229960000235 temsirolimus Drugs 0.000 claims description 8
• 230000001419 dependent effect Effects 0.000 claims description 7
• FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims description 6
• 229960003776 glatiramer acetate Drugs 0.000 claims description 6
• 239000007924 injection Substances 0.000 claims description 6
• 238000002347 injection Methods 0.000 claims description 6
• 108020004999 messenger RNA Proteins 0.000 claims description 6
• 241000124008 Mammalia Species 0.000 claims description 5
• 230000004075 alteration Effects 0.000 claims description 5
• KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 claims description 4
• 102000047918 Myelin Basic Human genes 0.000 claims description 4
• 101710107068 Myelin basic protein Proteins 0.000 claims description 4
• 210000003007 myelin sheath Anatomy 0.000 claims description 4
• 208000012902 Nervous system disease Diseases 0.000 claims description 3
• 210000003169 central nervous system Anatomy 0.000 claims description 3
• 230000006378 damage Effects 0.000 claims description 3
• 230000004952 protein activity Effects 0.000 claims description 3
• 101001054334 Homo sapiens Interferon beta Proteins 0.000 claims description 2
• 102100026720 Interferon beta Human genes 0.000 claims description 2
• 235000018102 proteins Nutrition 0.000 description 69
• 102000004127 Cytokines Human genes 0.000 description 44
• 108090000695 Cytokines Proteins 0.000 description 44
• 108020001507 fusion proteins Proteins 0.000 description 42
• 102000037865 fusion proteins Human genes 0.000 description 42
• 241001529936 Murinae Species 0.000 description 41
• -1 [L-11-13 Proteins 0.000 description 33
• 239000003112 inhibitor Substances 0.000 description 33
• 239000003795 chemical substances by application Substances 0.000 description 30
• 239000002773 nucleotide Substances 0.000 description 29
• 125000003729 nucleotide group Chemical group 0.000 description 29
• 235000001014 amino acid Nutrition 0.000 description 28
• 210000001744 T-lymphocyte Anatomy 0.000 description 27
• 241000699670 Mus sp. Species 0.000 description 25
• 229940024606 amino acid Drugs 0.000 description 24
• 150000001413 amino acids Chemical class 0.000 description 23
• 108060003951 Immunoglobulin Proteins 0.000 description 21
• 102000018358 immunoglobulin Human genes 0.000 description 21
• 230000035755 proliferation Effects 0.000 description 21
• 150000007523 nucleic acids Chemical group 0.000 description 19
• 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 18
• 230000001965 increasing effect Effects 0.000 description 18
• 239000000203 mixture Substances 0.000 description 18
• 102000005962 receptors Human genes 0.000 description 18
• 108020003175 receptors Proteins 0.000 description 18
• 229940124597 therapeutic agent Drugs 0.000 description 18
• 108010002350 Interleukin-2 Proteins 0.000 description 17
• 102000000588 Interleukin-2 Human genes 0.000 description 17
• 102100040247 Tumor necrosis factor Human genes 0.000 description 17
• 210000002865 immune cell Anatomy 0.000 description 16
• 102000039446 nucleic acids Human genes 0.000 description 16
• 108020004707 nucleic acids Proteins 0.000 description 16
• 239000013598 vector Substances 0.000 description 16
• 238000003556 assay Methods 0.000 description 15
• 230000006870 function Effects 0.000 description 15
• 230000003902 lesion Effects 0.000 description 15
• 210000000653 nervous system Anatomy 0.000 description 15
• 238000000338 in vitro Methods 0.000 description 13
• 230000028327 secretion Effects 0.000 description 13
• 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 description 12
• 102100023302 Myelin-oligodendrocyte glycoprotein Human genes 0.000 description 12
• 238000009396 hybridization Methods 0.000 description 12
• 102000040430 polynucleotide Human genes 0.000 description 12
• 108091033319 polynucleotide Proteins 0.000 description 12
• 239000002157 polynucleotide Substances 0.000 description 12
• 108010076504 Protein Sorting Signals Proteins 0.000 description 11
• 239000013604 expression vector Substances 0.000 description 11
• 210000004698 lymphocyte Anatomy 0.000 description 11
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 10
• 239000011230 binding agent Substances 0.000 description 10
• 201000010099 disease Diseases 0.000 description 10
• 239000012636 effector Substances 0.000 description 10
• 230000005713 exacerbation Effects 0.000 description 10
• 230000004044 response Effects 0.000 description 10
• 230000000875 corresponding effect Effects 0.000 description 9
• 102000003675 cytokine receptors Human genes 0.000 description 9
• 108010057085 cytokine receptors Proteins 0.000 description 9
• 229940079593 drug Drugs 0.000 description 9
• 239000000463 material Substances 0.000 description 9
• 108020004414 DNA Proteins 0.000 description 8
• 102000000589 Interleukin-1 Human genes 0.000 description 8
• 108010002352 Interleukin-1 Proteins 0.000 description 8
• 108700012920 TNF Proteins 0.000 description 8
• 206010003246 arthritis Diseases 0.000 description 8
• 239000003246 corticosteroid Substances 0.000 description 8
• 229960001334 corticosteroids Drugs 0.000 description 8
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 7
• 241000699666 Mus <mouse, genus> Species 0.000 description 7
• 230000000295 complement effect Effects 0.000 description 7
• 230000003247 decreasing effect Effects 0.000 description 7
• 230000004927 fusion Effects 0.000 description 7
• 210000001165 lymph node Anatomy 0.000 description 7
• 238000005259 measurement Methods 0.000 description 7
• 238000000746 purification Methods 0.000 description 7
• 102000009109 Fc receptors Human genes 0.000 description 6
• 108010087819 Fc receptors Proteins 0.000 description 6
• 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 6
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 6
• 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 6
• 108090000978 Interleukin-4 Proteins 0.000 description 6
• 102000004388 Interleukin-4 Human genes 0.000 description 6
• 241001465754 Metazoa Species 0.000 description 6
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
• 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 6
• 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 6
• 125000000539 amino acid group Chemical group 0.000 description 6
• 230000008859 change Effects 0.000 description 6
• 230000016396 cytokine production Effects 0.000 description 6
• 239000003102 growth factor Substances 0.000 description 6
• 230000010076 replication Effects 0.000 description 6
• 210000004989 spleen cell Anatomy 0.000 description 6
• 239000013589 supplement Substances 0.000 description 6
• 210000001519 tissue Anatomy 0.000 description 6
• 102000003298 tumor necrosis factor receptor Human genes 0.000 description 6
• 102000004190 Enzymes Human genes 0.000 description 5
• 108090000790 Enzymes Proteins 0.000 description 5
• 102000012745 Immunoglobulin Subunits Human genes 0.000 description 5
• 108010079585 Immunoglobulin Subunits Proteins 0.000 description 5
• 102000003816 Interleukin-13 Human genes 0.000 description 5
• 108090000176 Interleukin-13 Proteins 0.000 description 5
• 241000699660 Mus musculus Species 0.000 description 5
• 108010010974 Proteolipids Proteins 0.000 description 5
• 102000016202 Proteolipids Human genes 0.000 description 5
• 210000003719 b-lymphocyte Anatomy 0.000 description 5
• 230000004071 biological effect Effects 0.000 description 5
• 230000015572 biosynthetic process Effects 0.000 description 5
• 239000003153 chemical reaction reagent Substances 0.000 description 5
• 238000002648 combination therapy Methods 0.000 description 5
• 150000001875 compounds Chemical class 0.000 description 5
• 239000003937 drug carrier Substances 0.000 description 5
• 239000003446 ligand Substances 0.000 description 5
• 238000002595 magnetic resonance imaging Methods 0.000 description 5
• 238000010172 mouse model Methods 0.000 description 5
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 5
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
• 230000001105 regulatory effect Effects 0.000 description 5
• 230000011664 signaling Effects 0.000 description 5
• 150000003384 small molecules Chemical class 0.000 description 5
• 238000011830 transgenic mouse model Methods 0.000 description 5
• 241000894006 Bacteria Species 0.000 description 4
• 108010029697 CD40 Ligand Proteins 0.000 description 4
• 102100032937 CD40 ligand Human genes 0.000 description 4
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 4
• 108010036949 Cyclosporine Proteins 0.000 description 4
• 241000238631 Hexapoda Species 0.000 description 4
• 241000282412 Homo Species 0.000 description 4
• 101001010593 Homo sapiens Interleukin-21 receptor Proteins 0.000 description 4
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 4
• 102000004560 Interleukin-12 Receptors Human genes 0.000 description 4
• 108010017515 Interleukin-12 Receptors Proteins 0.000 description 4
• 108090000172 Interleukin-15 Proteins 0.000 description 4
• 229940122985 Peptide agonist Drugs 0.000 description 4
• 108020004511 Recombinant DNA Proteins 0.000 description 4
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
• 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
• 210000004369 blood Anatomy 0.000 description 4
• 239000008280 blood Substances 0.000 description 4
• 230000003915 cell function Effects 0.000 description 4
• 230000001413 cellular effect Effects 0.000 description 4
• 230000001684 chronic effect Effects 0.000 description 4
• 229960001265 ciclosporin Drugs 0.000 description 4
• MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 4
• 229940038717 copaxone Drugs 0.000 description 4
• 229930182912 cyclosporin Natural products 0.000 description 4
• 239000000824 cytostatic agent Substances 0.000 description 4
• 231100000433 cytotoxic Toxicity 0.000 description 4
• 239000002254 cytotoxic agent Substances 0.000 description 4
• 230000001472 cytotoxic effect Effects 0.000 description 4
• 230000000779 depleting effect Effects 0.000 description 4
• 238000010790 dilution Methods 0.000 description 4
• 239000012895 dilution Substances 0.000 description 4
• 239000003623 enhancer Substances 0.000 description 4
• 230000002068 genetic effect Effects 0.000 description 4
• 238000003384 imaging method Methods 0.000 description 4
• 230000001900 immune effect Effects 0.000 description 4
• 230000003053 immunization Effects 0.000 description 4
• 229960003444 immunosuppressant agent Drugs 0.000 description 4
• 239000003018 immunosuppressive agent Substances 0.000 description 4
• 210000003000 inclusion body Anatomy 0.000 description 4
• 230000006698 induction Effects 0.000 description 4
• 238000001990 intravenous administration Methods 0.000 description 4
• 239000007788 liquid Substances 0.000 description 4
• 239000003550 marker Substances 0.000 description 4
• 230000002503 metabolic effect Effects 0.000 description 4
• 230000037361 pathway Effects 0.000 description 4
• 239000013612 plasmid Substances 0.000 description 4
• 239000013615 primer Substances 0.000 description 4
• 230000009467 reduction Effects 0.000 description 4
• 230000035945 sensitivity Effects 0.000 description 4
• 239000011780 sodium chloride Substances 0.000 description 4
• 230000004083 survival effect Effects 0.000 description 4
• 238000002560 therapeutic procedure Methods 0.000 description 4
• OQANPHBRHBJGNZ-FYJGNVAPSA-N (3e)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 3
• 241000283690 Bos taurus Species 0.000 description 3
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
• 241000701022 Cytomegalovirus Species 0.000 description 3
• 108010052167 Dihydroorotate Dehydrogenase Proteins 0.000 description 3
• 102100032823 Dihydroorotate dehydrogenase (quinone), mitochondrial Human genes 0.000 description 3
• XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 3
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
• 102000003839 Human Proteins Human genes 0.000 description 3
• 108090000144 Human Proteins Proteins 0.000 description 3
• 206010061218 Inflammation Diseases 0.000 description 3
• 108010050904 Interferons Proteins 0.000 description 3
• 102000014150 Interferons Human genes 0.000 description 3
• 102000003812 Interleukin-15 Human genes 0.000 description 3
• 102000003810 Interleukin-18 Human genes 0.000 description 3
• 108090000171 Interleukin-18 Proteins 0.000 description 3
• 108090001005 Interleukin-6 Proteins 0.000 description 3
• 108010002586 Interleukin-7 Proteins 0.000 description 3
• 102000015696 Interleukins Human genes 0.000 description 3
• 108010063738 Interleukins Proteins 0.000 description 3
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
• 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 3
• 108091028043 Nucleic acid sequence Proteins 0.000 description 3
• 208000007542 Paresis Diseases 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 108010017324 STAT3 Transcription Factor Proteins 0.000 description 3
• 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 3
• 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 3
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 3
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
• 230000004913 activation Effects 0.000 description 3
• 239000004480 active ingredient Substances 0.000 description 3
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 3
• 229960002170 azathioprine Drugs 0.000 description 3
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 3
• 230000037396 body weight Effects 0.000 description 3
• 238000007796 conventional method Methods 0.000 description 3
• 230000001461 cytolytic effect Effects 0.000 description 3
• 230000006735 deficit Effects 0.000 description 3
• 238000001514 detection method Methods 0.000 description 3
• 238000011161 development Methods 0.000 description 3
• 230000018109 developmental process Effects 0.000 description 3
• 238000003745 diagnosis Methods 0.000 description 3
• 230000004069 differentiation Effects 0.000 description 3
• 238000005516 engineering process Methods 0.000 description 3
• 239000002532 enzyme inhibitor Substances 0.000 description 3
• 239000012894 fetal calf serum Substances 0.000 description 3
• 238000009472 formulation Methods 0.000 description 3
• 238000007429 general method Methods 0.000 description 3
• 239000001963 growth medium Substances 0.000 description 3
• 238000002649 immunization Methods 0.000 description 3
• 230000002163 immunogen Effects 0.000 description 3
• 230000009851 immunogenic response Effects 0.000 description 3
• 230000006872 improvement Effects 0.000 description 3
• 230000004054 inflammatory process Effects 0.000 description 3
• 230000002401 inhibitory effect Effects 0.000 description 3
• 238000005304 joining Methods 0.000 description 3
• 230000000670 limiting effect Effects 0.000 description 3
• 239000011159 matrix material Substances 0.000 description 3
• 239000012528 membrane Substances 0.000 description 3
• 210000000822 natural killer cell Anatomy 0.000 description 3
• 208000004296 neuralgia Diseases 0.000 description 3
• 229960005434 oxybutynin Drugs 0.000 description 3
• 230000036961 partial effect Effects 0.000 description 3
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
• 229960005205 prednisolone Drugs 0.000 description 3
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 3
• 230000002265 prevention Effects 0.000 description 3
• 230000004043 responsiveness Effects 0.000 description 3
• 238000004007 reversed phase HPLC Methods 0.000 description 3
• 241000894007 species Species 0.000 description 3
• 238000010254 subcutaneous injection Methods 0.000 description 3
• 238000006467 substitution reaction Methods 0.000 description 3
• 229960001940 sulfasalazine Drugs 0.000 description 3
• 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 3
• 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 3
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
• 241000701161 unidentified adenovirus Species 0.000 description 3
• 230000003612 virological effect Effects 0.000 description 3
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
• GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 2
• HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 2
• ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 2
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
• 239000005541 ACE inhibitor Substances 0.000 description 2
• 229920000936 Agarose Polymers 0.000 description 2
• 206010003591 Ataxia Diseases 0.000 description 2
• 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 2
• KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 2
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
• 238000011740 C57BL/6 mouse Methods 0.000 description 2
• 102000014914 Carrier Proteins Human genes 0.000 description 2
• 108090000426 Caspase-1 Proteins 0.000 description 2
• 229930105110 Cyclosporin A Natural products 0.000 description 2
• 239000003155 DNA primer Substances 0.000 description 2
• 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 2
• 241000588724 Escherichia coli Species 0.000 description 2
• 108010041356 Estrogen Receptor beta Proteins 0.000 description 2
• 102100029951 Estrogen receptor beta Human genes 0.000 description 2
• 229940123414 Folate antagonist Drugs 0.000 description 2
• UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 102000003886 Glycoproteins Human genes 0.000 description 2
• 108090000288 Glycoproteins Proteins 0.000 description 2
• 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 2
• 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 2
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
• 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 2
• 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 2
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
• 102000010787 Interleukin-4 Receptors Human genes 0.000 description 2
• 108010038486 Interleukin-4 Receptors Proteins 0.000 description 2
• 108010002616 Interleukin-5 Proteins 0.000 description 2
• 102000000743 Interleukin-5 Human genes 0.000 description 2
• 102000004889 Interleukin-6 Human genes 0.000 description 2
• 108010002335 Interleukin-9 Proteins 0.000 description 2
• UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 2
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
• FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 2
• 208000007101 Muscle Cramp Diseases 0.000 description 2
• 208000008238 Muscle Spasticity Diseases 0.000 description 2
• 206010028980 Neoplasm Diseases 0.000 description 2
• 108010035766 P-Selectin Proteins 0.000 description 2
• 102100023472 P-selectin Human genes 0.000 description 2
• 239000012826 P38 inhibitor Substances 0.000 description 2
• 238000012408 PCR amplification Methods 0.000 description 2
• 206010033799 Paralysis Diseases 0.000 description 2
• 108010081690 Pertussis Toxin Proteins 0.000 description 2
• 102000015439 Phospholipases Human genes 0.000 description 2
• 108010064785 Phospholipases Proteins 0.000 description 2
• 108010026552 Proteome Proteins 0.000 description 2
• 239000008156 Ringer's lactate solution Substances 0.000 description 2
• 238000011803 SJL/J (JAX™ mice strain) Methods 0.000 description 2
• 229920002684 Sepharose Polymers 0.000 description 2
• 230000005867 T cell response Effects 0.000 description 2
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
• 239000004473 Threonine Substances 0.000 description 2
• 108010022394 Threonine synthase Proteins 0.000 description 2
• 102000000887 Transcription factor STAT Human genes 0.000 description 2
• 108050007918 Transcription factor STAT Proteins 0.000 description 2
• 206010044565 Tremor Diseases 0.000 description 2
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
• MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 2
• 239000012190 activator Substances 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 239000000464 adrenergic agent Substances 0.000 description 2
• 235000004279 alanine Nutrition 0.000 description 2
• 229960000711 alprostadil Drugs 0.000 description 2
• 229940124599 anti-inflammatory drug Drugs 0.000 description 2
• 230000003110 anti-inflammatory effect Effects 0.000 description 2
• 239000003146 anticoagulant agent Substances 0.000 description 2
• 229960004676 antithrombotic agent Drugs 0.000 description 2
• 201000007201 aphasia Diseases 0.000 description 2
• 230000006907 apoptotic process Effects 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 125000003118 aryl group Chemical group 0.000 description 2
• 230000001363 autoimmune Effects 0.000 description 2
• 229960000794 baclofen Drugs 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
• 108091008324 binding proteins Proteins 0.000 description 2
• 238000001574 biopsy Methods 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 201000011510 cancer Diseases 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 2
• 229960000590 celecoxib Drugs 0.000 description 2
• RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
• 230000024245 cell differentiation Effects 0.000 description 2
• 230000004663 cell proliferation Effects 0.000 description 2
• 229960003405 ciprofloxacin Drugs 0.000 description 2
• 239000004074 complement inhibitor Substances 0.000 description 2
• 239000002299 complementary DNA Substances 0.000 description 2
• 229940111134 coxibs Drugs 0.000 description 2
• 239000012228 culture supernatant Substances 0.000 description 2
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
• 238000004163 cytometry Methods 0.000 description 2
• 230000001086 cytosolic effect Effects 0.000 description 2
• 210000004443 dendritic cell Anatomy 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• 229960004281 desmopressin Drugs 0.000 description 2
• NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 2
• 102000004419 dihydrofolate reductase Human genes 0.000 description 2
• 239000000539 dimer Substances 0.000 description 2
• 238000009826 distribution Methods 0.000 description 2
• 229940018602 docusate Drugs 0.000 description 2
• 230000002255 enzymatic effect Effects 0.000 description 2
• 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• 230000003394 haemopoietic effect Effects 0.000 description 2
• 230000035876 healing Effects 0.000 description 2
• 208000010726 hind limb paralysis Diseases 0.000 description 2
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
• 102000054751 human RUNX1T1 Human genes 0.000 description 2
• 210000004408 hybridoma Anatomy 0.000 description 2
• 229960001680 ibuprofen Drugs 0.000 description 2
• 230000028993 immune response Effects 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 238000003018 immunoassay Methods 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• 238000010348 incorporation Methods 0.000 description 2
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
• 230000003993 interaction Effects 0.000 description 2
• 229940047124 interferons Drugs 0.000 description 2
• 239000007928 intraperitoneal injection Substances 0.000 description 2
• 238000002642 intravenous therapy Methods 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• 229960000310 isoleucine Drugs 0.000 description 2
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
• 150000002632 lipids Chemical class 0.000 description 2
• 230000000527 lymphocytic effect Effects 0.000 description 2
• 229940124302 mTOR inhibitor Drugs 0.000 description 2
• 210000002540 macrophage Anatomy 0.000 description 2
• 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 2
• 230000001404 mediated effect Effects 0.000 description 2
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical class S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
• 229960004584 methylprednisolone Drugs 0.000 description 2
• 235000010446 mineral oil Nutrition 0.000 description 2
• 239000002480 mineral oil Substances 0.000 description 2
• ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 2
• RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 2
• 229960004866 mycophenolate mofetil Drugs 0.000 description 2
• 210000005036 nerve Anatomy 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 235000019198 oils Nutrition 0.000 description 2
• XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
• 239000002571 phosphodiesterase inhibitor Substances 0.000 description 2
• 239000003428 phospholipase inhibitor Substances 0.000 description 2
• 230000026731 phosphorylation Effects 0.000 description 2
• 238000006366 phosphorylation reaction Methods 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• 238000002360 preparation method Methods 0.000 description 2
• 230000000770 proinflammatory effect Effects 0.000 description 2
• 230000002062 proliferating effect Effects 0.000 description 2
• 230000009696 proliferative response Effects 0.000 description 2
• 230000000069 prophylactic effect Effects 0.000 description 2
• GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 2
• 239000003379 purinergic P1 receptor agonist Substances 0.000 description 2
• 238000003259 recombinant expression Methods 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 239000011347 resin Substances 0.000 description 2
• 229920005989 resin Polymers 0.000 description 2
• 108091008146 restriction endonucleases Proteins 0.000 description 2
• 210000002966 serum Anatomy 0.000 description 2
• 230000019491 signal transduction Effects 0.000 description 2
• BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
• 239000001488 sodium phosphate Substances 0.000 description 2
• 229910000162 sodium phosphate Inorganic materials 0.000 description 2
• 239000000243 solution Substances 0.000 description 2
• 208000018198 spasticity Diseases 0.000 description 2
• 210000004988 splenocyte Anatomy 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 230000004936 stimulating effect Effects 0.000 description 2
• 239000007929 subcutaneous injection Substances 0.000 description 2
• NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
• 239000003826 tablet Substances 0.000 description 2
• 238000012360 testing method Methods 0.000 description 2
• ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
• 229940104230 thymidine Drugs 0.000 description 2
• XFYDIVBRZNQMJC-UHFFFAOYSA-N tizanidine Chemical compound ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 XFYDIVBRZNQMJC-UHFFFAOYSA-N 0.000 description 2
• 229960000488 tizanidine Drugs 0.000 description 2
• 230000009261 transgenic effect Effects 0.000 description 2
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
• 239000002447 tumor necrosis factor alpha converting enzyme inhibitor Substances 0.000 description 2
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
• 239000004474 valine Substances 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• 239000013603 viral vector Substances 0.000 description 2
• AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
• XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
• ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
• RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
• IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
• HBOMLICNUCNMMY-KJFJCRTCSA-N 1-[(4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-KJFJCRTCSA-N 0.000 description 1
• OZOMQRBLCMDCEG-CHHVJCJISA-N 1-[(z)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N/N1C(=O)NC(=O)C1 OZOMQRBLCMDCEG-CHHVJCJISA-N 0.000 description 1
• DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
• YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 description 1
• LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
• 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
• HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
• 206010054196 Affect lability Diseases 0.000 description 1
• 101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
• KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 1
• 206010002091 Anaesthesia Diseases 0.000 description 1
• 241000024188 Andala Species 0.000 description 1
• 208000019901 Anxiety disease Diseases 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 208000030767 Autoimmune encephalitis Diseases 0.000 description 1
• 238000012935 Averaging Methods 0.000 description 1
• 244000063299 Bacillus subtilis Species 0.000 description 1
• 235000014469 Bacillus subtilis Nutrition 0.000 description 1
• 108010077805 Bacterial Proteins Proteins 0.000 description 1
• 102100039705 Beta-2 adrenergic receptor Human genes 0.000 description 1
• 101710152983 Beta-2 adrenergic receptor Proteins 0.000 description 1
• 101150013553 CD40 gene Proteins 0.000 description 1
• 101150071146 COX2 gene Proteins 0.000 description 1
• 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 1
• 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 206010008025 Cerebellar ataxia Diseases 0.000 description 1
• 206010008072 Cerebellar syndrome Diseases 0.000 description 1
• 241001227713 Chiron Species 0.000 description 1
• 206010009346 Clonus Diseases 0.000 description 1
• 102000000989 Complement System Proteins Human genes 0.000 description 1
• 108010069112 Complement System Proteins Proteins 0.000 description 1
• 206010010774 Constipation Diseases 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• 102000053602 DNA Human genes 0.000 description 1
• 206010012289 Dementia Diseases 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 101100366888 Dictyostelium discoideum dstA gene Proteins 0.000 description 1
• 208000003164 Diplopia Diseases 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 206010013887 Dysarthria Diseases 0.000 description 1
• 208000014094 Dystonic disease Diseases 0.000 description 1
• 238000002965 ELISA Methods 0.000 description 1
• 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 241001492222 Epicoccum Species 0.000 description 1
• YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
• 208000010228 Erectile Dysfunction Diseases 0.000 description 1
• 241000206602 Eukaryota Species 0.000 description 1
• 241001539473 Euphoria Species 0.000 description 1
• 206010015535 Euphoric mood Diseases 0.000 description 1
• 208000034347 Faecal incontinence Diseases 0.000 description 1
• 208000021663 Female sexual arousal disease Diseases 0.000 description 1
• 229910052688 Gadolinium Inorganic materials 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 206010060891 General symptom Diseases 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 102000005720 Glutathione transferase Human genes 0.000 description 1
• 108010070675 Glutathione transferase Proteins 0.000 description 1
• BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
• 102000009465 Growth Factor Receptors Human genes 0.000 description 1
• 108010009202 Growth Factor Receptors Proteins 0.000 description 1
• 108010051696 Growth Hormone Proteins 0.000 description 1
• 206010019468 Hemiplegia Diseases 0.000 description 1
• 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
• 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
• 101100072407 Homo sapiens IL21R gene Proteins 0.000 description 1
• 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
• 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
• 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
• 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 description 1
• 101000960954 Homo sapiens Interleukin-18 Proteins 0.000 description 1
• 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
• 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
• 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
• 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 1
• 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
• 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
• 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
• 206010021118 Hypotonia Diseases 0.000 description 1
• 239000003458 I kappa b kinase inhibitor Substances 0.000 description 1
• 101150106931 IFNG gene Proteins 0.000 description 1
• 101150076458 ILI2 gene Proteins 0.000 description 1
• 206010022520 Intention tremor Diseases 0.000 description 1
• 108010005716 Interferon beta-1a Proteins 0.000 description 1
• 102100039065 Interleukin-1 beta Human genes 0.000 description 1
• 102000004559 Interleukin-13 Receptors Human genes 0.000 description 1
• 108010017511 Interleukin-13 Receptors Proteins 0.000 description 1
• 102000004556 Interleukin-15 Receptors Human genes 0.000 description 1
• 108010017535 Interleukin-15 Receptors Proteins 0.000 description 1
• 102000004557 Interleukin-18 Receptors Human genes 0.000 description 1
• 108010017537 Interleukin-18 Receptors Proteins 0.000 description 1
• 102100035017 Interleukin-18-binding protein Human genes 0.000 description 1
• 101710205006 Interleukin-18-binding protein Proteins 0.000 description 1
• 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
• 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
• 102100030699 Interleukin-21 receptor Human genes 0.000 description 1
• 108090001007 Interleukin-8 Proteins 0.000 description 1
• DHUZAAUGHUHIDS-ONEGZZNKSA-N Isomyristicin Chemical compound COC1=CC(\C=C\C)=CC2=C1OCO2 DHUZAAUGHUHIDS-ONEGZZNKSA-N 0.000 description 1
• ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
• 241000235649 Kluyveromyces Species 0.000 description 1
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• 102000016267 Leptin Human genes 0.000 description 1
• 108010092277 Leptin Proteins 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
• ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
• 102100026907 Mitogen-activated protein kinase kinase kinase 8 Human genes 0.000 description 1
• 101710164353 Mitogen-activated protein kinase kinase kinase 8 Proteins 0.000 description 1
• 208000034819 Mobility Limitation Diseases 0.000 description 1
• 206010027925 Monoparesis Diseases 0.000 description 1
• 206010027951 Mood swings Diseases 0.000 description 1
• 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 1
• 101001044384 Mus musculus Interferon gamma Proteins 0.000 description 1
• 208000007379 Muscle Hypotonia Diseases 0.000 description 1
• 206010028289 Muscle atrophy Diseases 0.000 description 1
• 241001049988 Mycobacterium tuberculosis H37Ra Species 0.000 description 1
• 208000002033 Myoclonus Diseases 0.000 description 1
• 206010028632 Myokymia Diseases 0.000 description 1
• BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 1
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
• 241001045988 Neogene Species 0.000 description 1
• PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
• 206010063534 Ocular dysmetria Diseases 0.000 description 1
• 208000003435 Optic Neuritis Diseases 0.000 description 1
• 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 description 1
• 101710137390 P-selectin glycoprotein ligand 1 Proteins 0.000 description 1
• 101150012195 PREB gene Proteins 0.000 description 1
• 101150000187 PTGS2 gene Proteins 0.000 description 1
• 206010033885 Paraparesis Diseases 0.000 description 1
• 206010033892 Paraplegia Diseases 0.000 description 1
• AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
• 241000237988 Patellidae Species 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 206010034701 Peroneal nerve palsy Diseases 0.000 description 1
• QPFYXYFORQJZEC-FOCLMDBBSA-N Phenazopyridine Chemical compound NC1=NC(N)=CC=C1\N=N\C1=CC=CC=C1 QPFYXYFORQJZEC-FOCLMDBBSA-N 0.000 description 1
• CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
• 206010034962 Photopsia Diseases 0.000 description 1
• 244000134552 Plantago ovata Species 0.000 description 1
• 235000003421 Plantago ovata Nutrition 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 description 1
• 239000009223 Psyllium Substances 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• 206010037714 Quadriplegia Diseases 0.000 description 1
• 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
• 206010063837 Reperfusion injury Diseases 0.000 description 1
• 208000005793 Restless legs syndrome Diseases 0.000 description 1
• 108010044012 STAT1 Transcription Factor Proteins 0.000 description 1
• 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
• 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 102100038803 Somatotropin Human genes 0.000 description 1
• 208000005392 Spasm Diseases 0.000 description 1
• 208000014604 Specific Language disease Diseases 0.000 description 1
• 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 1
• 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 1
• 238000000692 Student's t-test Methods 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
• 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
• 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
• 229940124674 VEGF-R inhibitor Drugs 0.000 description 1
• SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 1
• 208000012886 Vertigo Diseases 0.000 description 1
• 101100311214 Xenopus laevis stat3.1 gene Proteins 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 239000002253 acid Substances 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 239000011149 active material Substances 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 229960003805 amantadine Drugs 0.000 description 1
• DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
• 229960000836 amitriptyline Drugs 0.000 description 1
• KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 230000037005 anaesthesia Effects 0.000 description 1
• 238000001949 anaesthesia Methods 0.000 description 1
• 238000004458 analytical method Methods 0.000 description 1
• 230000033115 angiogenesis Effects 0.000 description 1
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
• 239000003957 anion exchange resin Substances 0.000 description 1
• 230000003042 antagnostic effect Effects 0.000 description 1
• 230000005875 antibody response Effects 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 230000036506 anxiety Effects 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 229940009100 aurothiomalate Drugs 0.000 description 1
• XJHSMFDIQHVMCY-UHFFFAOYSA-M aurothiomalic acid Chemical compound OC(=O)CC(S[Au])C(O)=O XJHSMFDIQHVMCY-UHFFFAOYSA-M 0.000 description 1
• 244000052616 bacterial pathogen Species 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
• 208000032257 benign familial neonatal 1 seizures Diseases 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 239000003613 bile acid Substances 0.000 description 1
• 229960000503 bisacodyl Drugs 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 210000000133 brain stem Anatomy 0.000 description 1
• SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
• 229960001058 bupropion Drugs 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
• BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
• 229960000623 carbamazepine Drugs 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
• 238000005341 cation exchange Methods 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 238000000423 cell based assay Methods 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 239000013592 cell lysate Substances 0.000 description 1
• 238000001516 cell proliferation assay Methods 0.000 description 1
• 230000008614 cellular interaction Effects 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 229940116592 central nervous system diagnostic radiopharmaceuticals Drugs 0.000 description 1
• 208000015114 central nervous system disease Diseases 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• 230000003196 chaotropic effect Effects 0.000 description 1
• 238000012412 chemical coupling Methods 0.000 description 1
• 230000014564 chemokine production Effects 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
• 229960003120 clonazepam Drugs 0.000 description 1
• 208000010877 cognitive disease Diseases 0.000 description 1
• 230000004154 complement system Effects 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 239000003636 conditioned culture medium Substances 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 229940109248 cromoglycate Drugs 0.000 description 1
• IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
• 210000004748 cultured cell Anatomy 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 229960001987 dantrolene Drugs 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 239000003398 denaturant Substances 0.000 description 1
• 238000000586 desensitisation Methods 0.000 description 1
• 239000003599 detergent Substances 0.000 description 1
• 201000003892 detrusor sphincter dyssynergia Diseases 0.000 description 1
• 229960003957 dexamethasone Drugs 0.000 description 1
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 239000008356 dextrose and sodium chloride injection Substances 0.000 description 1
• 239000008355 dextrose injection Substances 0.000 description 1
• 238000000502 dialysis Methods 0.000 description 1
• AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
• 229960003529 diazepam Drugs 0.000 description 1
• 229960001259 diclofenac Drugs 0.000 description 1
• DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 1
• 210000001840 diploid cell Anatomy 0.000 description 1
• POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 208000010118 dystonia Diseases 0.000 description 1
• 239000008144 emollient laxative Substances 0.000 description 1
• 230000001712 encephalitogenic effect Effects 0.000 description 1
• 239000002158 endotoxin Substances 0.000 description 1
• 238000001976 enzyme digestion Methods 0.000 description 1
• 239000003797 essential amino acid Substances 0.000 description 1
• 235000020776 essential amino acid Nutrition 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 238000013265 extended release Methods 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 206010016256 fatigue Diseases 0.000 description 1
• 230000002550 fecal effect Effects 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 229960002464 fluoxetine Drugs 0.000 description 1
• 230000037406 food intake Effects 0.000 description 1
• 230000037433 frameshift Effects 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 229960002870 gabapentin Drugs 0.000 description 1
• UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
• IZOOGPBRAOKZFK-UHFFFAOYSA-K gadopentetate Chemical compound [Gd+3].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O IZOOGPBRAOKZFK-UHFFFAOYSA-K 0.000 description 1
• 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 238000002523 gelfiltration Methods 0.000 description 1
• 238000001415 gene therapy Methods 0.000 description 1
• 210000004602 germ cell Anatomy 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• 229940049906 glutamate Drugs 0.000 description 1
• 229960002989 glutamic acid Drugs 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 235000011187 glycerol Nutrition 0.000 description 1
• 229960005150 glycerol Drugs 0.000 description 1
• 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 230000013595 glycosylation Effects 0.000 description 1
• 238000006206 glycosylation reaction Methods 0.000 description 1
• 239000000122 growth hormone Substances 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 206010019465 hemiparesis Diseases 0.000 description 1
• 108060003552 hemocyanin Proteins 0.000 description 1
• VBZWSGALLODQNC-UHFFFAOYSA-N hexafluoroacetone Chemical class FC(F)(F)C(=O)C(F)(F)F VBZWSGALLODQNC-UHFFFAOYSA-N 0.000 description 1
• 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
• VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 102000056549 human Fv Human genes 0.000 description 1
• 108700005872 human Fv Proteins 0.000 description 1
• 102000043557 human IFNG Human genes 0.000 description 1
• 102000056003 human IL15 Human genes 0.000 description 1
• 102000043959 human IL18 Human genes 0.000 description 1
• 102000057041 human TNF Human genes 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
• XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
• 229960004171 hydroxychloroquine Drugs 0.000 description 1
• 229960000930 hydroxyzine Drugs 0.000 description 1
• ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
• BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
• 229960004801 imipramine Drugs 0.000 description 1
• 230000003832 immune regulation Effects 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 108010023260 immunoglobulin Fv Proteins 0.000 description 1
• 230000016784 immunoglobulin production Effects 0.000 description 1
• 229940072221 immunoglobulins Drugs 0.000 description 1
• 201000001881 impotence Diseases 0.000 description 1
• 229960000905 indomethacin Drugs 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 239000013546 insoluble monolayer Substances 0.000 description 1
• 229940079322 interferon Drugs 0.000 description 1
• 229960004461 interferon beta-1a Drugs 0.000 description 1
• 102000044166 interleukin-18 binding protein Human genes 0.000 description 1
• 108010070145 interleukin-18 binding protein Proteins 0.000 description 1
• 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 1
• 201000001801 internuclear ophthalmoplegia Diseases 0.000 description 1
• 238000007917 intracranial administration Methods 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
• 229960001888 ipratropium Drugs 0.000 description 1
• 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
• 229960003350 isoniazid Drugs 0.000 description 1
• QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
• 150000002576 ketones Chemical class 0.000 description 1
• 229960004958 ketotifen Drugs 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 229940043355 kinase inhibitor Drugs 0.000 description 1
• 239000008141 laxative Substances 0.000 description 1
• 230000002475 laxative effect Effects 0.000 description 1
• 239000010410 layer Substances 0.000 description 1
• 229940039781 leptin Drugs 0.000 description 1
• NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 208000027905 limb weakness Diseases 0.000 description 1
• 231100000861 limb weakness Toxicity 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 239000004973 liquid crystal related substance Substances 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 210000003141 lower extremity Anatomy 0.000 description 1
• 210000002751 lymph Anatomy 0.000 description 1
• 230000001926 lymphatic effect Effects 0.000 description 1
• 210000003563 lymphoid tissue Anatomy 0.000 description 1
• VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
• 239000000347 magnesium hydroxide Substances 0.000 description 1
• 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
• 229960000816 magnesium hydroxide Drugs 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 210000003519 mature b lymphocyte Anatomy 0.000 description 1
• 229960001474 meclozine Drugs 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• 210000003593 megakaryocyte Anatomy 0.000 description 1
• 229960001929 meloxicam Drugs 0.000 description 1
• KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
• 229960004963 mesalazine Drugs 0.000 description 1
• 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
• 229960004011 methenamine Drugs 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 239000000693 micelle Substances 0.000 description 1
• 238000002493 microarray Methods 0.000 description 1
• 235000013336 milk Nutrition 0.000 description 1
• 239000008267 milk Substances 0.000 description 1
• 210000004080 milk Anatomy 0.000 description 1
• 229940042472 mineral oil Drugs 0.000 description 1
• 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
• 229960001156 mitoxantrone Drugs 0.000 description 1
• 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 1
• 229960001165 modafinil Drugs 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 102000035118 modified proteins Human genes 0.000 description 1
• 108091005573 modified proteins Proteins 0.000 description 1
• 238000001823 molecular biology technique Methods 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 239000002324 mouth wash Substances 0.000 description 1
• 229940051866 mouthwash Drugs 0.000 description 1
• 230000020763 muscle atrophy Effects 0.000 description 1
• 201000000585 muscular atrophy Diseases 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• 108010064578 myelin proteolipid protein (139-151) Proteins 0.000 description 1
• KDGKTJGPFXIBEB-UHFFFAOYSA-N n-hydroxyformamide Chemical compound ONC=O KDGKTJGPFXIBEB-UHFFFAOYSA-N 0.000 description 1
• 210000004296 naive t lymphocyte Anatomy 0.000 description 1
• 229960002009 naproxen Drugs 0.000 description 1
• CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
• 229960004398 nedocromil Drugs 0.000 description 1
• RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 description 1
• 101150091879 neo gene Proteins 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 238000010984 neurological examination Methods 0.000 description 1
• 230000002981 neuropathic effect Effects 0.000 description 1
• 208000021722 neuropathic pain Diseases 0.000 description 1
• 229960000564 nitrofurantoin Drugs 0.000 description 1
• NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
• 238000001151 non-parametric statistical test Methods 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 229960001158 nortriptyline Drugs 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 206010029864 nystagmus Diseases 0.000 description 1
• 208000028780 ocular motility disease Diseases 0.000 description 1
• 210000004248 oligodendroglia Anatomy 0.000 description 1
• QQBDLJCYGRGAKP-FOCLMDBBSA-N olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-FOCLMDBBSA-N 0.000 description 1
• 229960004110 olsalazine Drugs 0.000 description 1
• 206010030875 ophthalmoplegia Diseases 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical compound CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 description 1
• 229960000797 oxitropium Drugs 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 208000021090 palsy Diseases 0.000 description 1
• 229960001789 papaverine Drugs 0.000 description 1
• 244000045947 parasite Species 0.000 description 1
• 208000035824 paresthesia Diseases 0.000 description 1
• 229960002296 paroxetine Drugs 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 229960000761 pemoline Drugs 0.000 description 1
• NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
• 239000003208 petroleum Substances 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 229960001181 phenazopyridine Drugs 0.000 description 1
• 229960002036 phenytoin Drugs 0.000 description 1
• 229910000065 phosphene Inorganic materials 0.000 description 1
• 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
• 230000035479 physiological effects, processes and functions Effects 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• 229960002702 piroxicam Drugs 0.000 description 1
• QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
• 239000000902 placebo Substances 0.000 description 1
• 229940068196 placebo Drugs 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 238000003752 polymerase chain reaction Methods 0.000 description 1
• 231100000683 possible toxicity Toxicity 0.000 description 1
• 229960004618 prednisone Drugs 0.000 description 1
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 239000000047 product Substances 0.000 description 1
• 229960005439 propantheline bromide Drugs 0.000 description 1
• 230000000272 proprioceptive effect Effects 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 239000012460 protein solution Substances 0.000 description 1
• 229940070687 psyllium Drugs 0.000 description 1
• 208000022749 pupil disease Diseases 0.000 description 1
• 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
• 238000003753 real-time PCR Methods 0.000 description 1
• 229940044601 receptor agonist Drugs 0.000 description 1
• 239000000018 receptor agonist Substances 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 230000011514 reflex Effects 0.000 description 1
• 229940116176 remicade Drugs 0.000 description 1
• 238000003757 reverse transcription PCR Methods 0.000 description 1
• 102200111151 rs869312902 Human genes 0.000 description 1
• 229960002052 salbutamol Drugs 0.000 description 1
• 150000003839 salts Chemical class 0.000 description 1
• 229930182490 saponin Natural products 0.000 description 1
• 150000007949 saponins Chemical class 0.000 description 1
• 238000007423 screening assay Methods 0.000 description 1
• 230000001953 sensory effect Effects 0.000 description 1
• VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
• 229960002073 sertraline Drugs 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 229960003310 sildenafil Drugs 0.000 description 1
• 239000000741 silica gel Substances 0.000 description 1
• 229910002027 silica gel Inorganic materials 0.000 description 1
• 238000009097 single-agent therapy Methods 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 239000008354 sodium chloride injection Substances 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 229960003339 sodium phosphate Drugs 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 230000003381 solubilizing effect Effects 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 210000001082 somatic cell Anatomy 0.000 description 1
• 230000000392 somatic effect Effects 0.000 description 1
• VIDRYROWYFWGSY-UHFFFAOYSA-N sotalol hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 VIDRYROWYFWGSY-UHFFFAOYSA-N 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 125000006850 spacer group Chemical group 0.000 description 1
• 238000012289 standard assay Methods 0.000 description 1
• 238000000528 statistical test Methods 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 229960005404 sulfamethoxazole Drugs 0.000 description 1
• JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
• 231100000617 superantigen Toxicity 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
• 229960003676 tenidap Drugs 0.000 description 1
• LXIKEPCNDFVJKC-QXMHVHEDSA-N tenidap Chemical compound C12=CC(Cl)=CC=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 LXIKEPCNDFVJKC-QXMHVHEDSA-N 0.000 description 1
• 229960000195 terbutaline Drugs 0.000 description 1
• 229960000278 theophylline Drugs 0.000 description 1
• 238000004448 titration Methods 0.000 description 1
• 229960004045 tolterodine Drugs 0.000 description 1
• OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 108700012359 toxins Proteins 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 238000013519 translation Methods 0.000 description 1
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
• 206010044652 trigeminal neuralgia Diseases 0.000 description 1
• 239000013638 trimer Substances 0.000 description 1
• GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
• 108091005990 tyrosine-phosphorylated proteins Proteins 0.000 description 1
• 238000000108 ultra-filtration Methods 0.000 description 1
• 241000701447 unidentified baculovirus Species 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 1
• 229960002381 vardenafil Drugs 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 239000002525 vasculotropin inhibitor Substances 0.000 description 1
• 229960004688 venlafaxine Drugs 0.000 description 1
• PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
• 231100000889 vertigo Toxicity 0.000 description 1
• 206010047385 vestibular ataxia Diseases 0.000 description 1
• 244000052613 viral pathogen Species 0.000 description 1
• 230000000007 visual effect Effects 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1